(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

With new testing requirements, it’s not even clear whether new Covid or flu shots can be made available this fall.

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...